

| Gene Set | | IC(Δ) | p-value | FDR |
|--|----|----------------|----------|----------|
| | C1 | | | |
| CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP | | 0.935(0.003) | 2.62e-06 | 2.05e-05 |
| LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN | | 0.913(0.003) | 2.62e-06 | 2.05e-05 |
| COLDREN_GEFITINIB_RESISTANCE_DN | | 0.905(0.006) | 2.62e-06 | 2.05e-05 |
| LANDIS_BREAST_CANCER_PROGRESSION | | 0.903(0.005) | 2.62e-06 | 2.05e-05 |
| CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL | | 0.902(0.004) | 2.62e-06 | 2.05e-05 |
| CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL | | 0.902(0.003) | 2.62e-06 | 2.05e-05 |
| CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP | | 0.894(0.006) | 2.62e-06 | 2.05e-05 |
| LIM_MAMMARY_STEM_CELL_DN | | 0.881(0.005) | 2.62e-06 | 2.05e-05 |
| BOYALT_LIVER_CANCER_SUBCLASS_G1_UP | | 0.881(0.005) | 2.62e-06 | 2.05e-05 |
| AIGNER_ZEB1_TARGETS | | 0.879(0.006) | 2.62e-06 | 2.05e-05 |
| LANDIS_ERBB2_BREAST_TUMORS_324 | | 0.878(0.007) | 2.62e-06 | 2.05e-05 |
| CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP | | 0.878(0.005) | 2.62e-06 | 2.05e-05 |
| WALLACE_PROSTATE_CANCER_UP | | 0.873(0.006) | 2.62e-06 | 2.05e-05 |
| WAMUNYOKOLI_OVARIAN_CANCER_LMP | | 0.872(0.006) | 2.62e-06 | 2.05e-05 |
| LANDIS_BREAST_CANCER_PROGRESSION_UP | | 0.872(0.007) | 2.62e-06 | 2.05e-05 |
| GROGER_EMT_DN | | 0.869(0.007) | 2.62e-06 | 2.05e-05 |
| WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP | | 0.867(0.008) | 2.62e-06 | 2.05e-05 |
| SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN | | 0.864(0.007) | 2.62e-06 | 2.05e-05 |
| LIM_MAMMARY_LUMINAL_MATURE_UP | | 0.856(0.007) | 2.62e-06 | 2.05e-05 |
| TAUBE_EMT_DN | | 0.856(0.007) | 2.62e-06 | 2.05e-05 |
| VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY | | -0.811(0.009) | 2.62e-06 | 1.16e-05 |
| BOQUEST_STEM_CELL | | -0.814(0.009) | 2.62e-06 | 1.16e-05 |
| JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION | | -0.818(0.009) | 2.62e-06 | 1.16e-05 |
| JAEGER_METASTASIS | | -0.821(0.008) | 2.62e-06 | 1.16e-05 |
| SENGUPTA_NASOPHARYNGEAL_CARCINOMA | | -0.828(0.007) | 2.62e-06 | 1.16e-05 |
| NGO_MALIGNANT_GLIOMA_1P_LOH | | -0.831(0.015) | 2.62e-06 | 1.16e-05 |
| CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN | | -0.834(0.007) | 2.62e-06 | 1.16e-05 |
| MIKHAYLOVA_OXIDATIVE_STRESS_RESPONSE_VIA_VHL_UP | | -0.841(0.014) | 2.62e-06 | 1.16e-05 |
| TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL | | -0.844(0.007) | 2.62e-06 | 1.16e-05 |
| COLDREN_GEFITINIB_RESISTANCE_UP | | -0.851(0.007) | 2.62e-06 | 1.16e-05 |
| SMID_BREAST_CANCER_NORMAL_LIKE | | -0.863(0.006) | 2.62e-06 | 1.16e-05 |
| ONDER_CDH1_TARGETS_2 | | -0.869(0.007) | 2.62e-06 | 1.16e-05 |
| ROY_WOUND_BLOOD_VESSEL | | -0.873(0.006) | 2.62e-06 | 1.16e-05 |
| SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE | | -0.873(0.006) | 2.62e-06 | 1.16e-05 |
| LIM_MAMMARY_STEM_CELL | | -0.877(0.004) | 2.62e-06 | 1.16e-05 |
| GU_PDEF_TARGETS | | -0.880(0.005) | 2.62e-06 | 1.16e-05 |
| TAUBE_EMT | | -0.881(0.005) | 2.62e-06 | 1.16e-05 |
| LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL | | -0.885(0.004) | 2.62e-06 | 1.16e-05 |
| GROGER_EMT | | -0.892(0.005) | 2.62e-06 | 1.16e-05 |
| COLDREN_GEFITINIB_RESISTANCE | | -0.904(0.005) | 2.62e-06 | 1.16e-05 |